The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Nicole Ventrone
Advertisement
Articles by Nicole Ventrone
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
2
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
3
Closing the Pediatric Evidence Gap
4
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
5